10806XAB8

Bridgebio Pharma, Inc.

Could not find a ticker for this position, may be a filing error

A biopharmaceutical company developing medicines for genetic diseases, BridgeBio's approved products include Attruby for a heart condition called ATTR-CM and Truseltiq for bile-duct cancer. Founded in 2015, its name reflects a mission of 'bridging' genetic research to patients, and it runs a hub-and-spoke model where small teams advance each drug. Its experimental oral therapy for achondroplasia was the first-ever treatment for children with the condition to earn the FDA's Breakthrough Therapy designation.

2.50% Convertible Senior Notes due 2027